Speakers: Dorien Feyaerts, Ph.D. (Post-doctoral researcher at Stanford University School of Medicine)
Original Broadcast date: November 5, 2021
Coronavirus disease 2019 (COVID-19) results in heterogenous responses, from asymptomatic to severe respiratory distress that can lead to death. To date, most COVID-19 studies have compared severe cases with healthy controls. In this webinar, Dr. Fevaerts describes how plasma and single-cell proteomics using Olink® PEA technology and mass cytometry, respectively, were combined to identify protein signatures that can classify mild, moderate, and severe responses to COVID-19 infection. Their data reveal a dysregulation in protein signaling and immune cells.
The webinar covers the following points:
- Multi-omic modeling of plasma and single-cell proteomics categorizes COVID-19 severity
- Protein profiling of plasma using Olink® Explore platform
- Dysregulation of JAK/STAT, NF-kB, and MAPK/mTOR immune signaling associated with COVID-19 severity
- Altered levels of immune cells associated with COVID-19 severity
If you have any questions about Olink, please contact us at info@olink.com.
